Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Ilaris Generic Name & Formulations
Legal Class
Rx
General Description
Canakinumab 150mg/mL soln for SC inj; 150mg/vial lyophilized pwd for SC inj after reconstitution; preservative-free.
Pharmacological Class
Interleukin-1beta blocker.
How Supplied
Single-dose vial—1
Manufacturer
Generic Availability
NO
Ilaris Indications
Indications
Active Still's disease, including adult-onset Still's disease (AOSD) and systemic juvenile idiopathic arthritis (SJIA).
Ilaris Dosage and Administration
Adults and Children
<2yrs: not established. Avoid injecting into scar tissue. Give as SC inj every 4 weeks. ≥2yrs (≥7.5kg): 4mg/kg; max 300mg.
Ilaris Contraindications
Not Applicable
Ilaris Boxed Warnings
Not Applicable
Ilaris Warnings/Precautions
Warnings/Precautions
Do not start in patients with active infection; discontinue if serious infection develops. History of recurring infections or conditions that predispose to infection. Test for and treat TB before starting therapy. Discontinue if severe hypersensitivity reaction occurs. Patients should receive all recommended vaccines (eg, pneumococcal, influenza) prior to initiating therapy. Macrophage activation syndrome (esp. in Still's disease). Pregnancy. Nursing mothers.
Ilaris Pharmacokinetics
See Literature
Ilaris Interactions
Interactions
Concomitant TNF inhibitors, other IL-1 blockers, live vaccines: not recommended. Monitor warfarin, other agents with narrow therapeutic indexes; may need dose adjustments.
Ilaris Adverse Reactions
Adverse Reactions
Nasopharyngitis, diarrhea, influenza, rhinitis, nausea, headache, bronchitis, gastroenteritis, pharyngitis, inj site reactions, weight increased, musculoskeletal pain, vertigo, abdominal pain; increased risk of infections, malignancies.
Ilaris Clinical Trials
See Literature
Ilaris Note
Not Applicable
Ilaris Patient Counseling
See Literature
Ilaris Generic Name & Formulations
Legal Class
Rx
General Description
Canakinumab 150mg/mL soln for SC inj; 150mg/vial lyophilized pwd for SC inj after reconstitution; preservative-free.
Pharmacological Class
Interleukin-1beta blocker.
How Supplied
Single-dose vial—1
Manufacturer
Generic Availability
NO
Ilaris Indications
Indications
Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and children ≥4yrs of age including: Familial Cold Autoinflammatory Syndrome (FCAS); Muckle-Wells Syndrome (MWS). Treatment of Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS), Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD), and Familial Mediterranean Fever (FMF) in adults and children.
Ilaris Dosage and Administration
Adults and Children
Avoid injecting into scar tissue. CAPS: Give as SC inj every 8 weeks. <4yrs: not established. ≥4yrs: (≥15–≤40kg): 2mg/kg; children (15–40kg) with inadequate response: may increase to 3mg/kg; (>40kg): 150mg. TRAPS, HIDS/MKD, FMF: Give as SC inj every 4 weeks. <2yrs: not recommended. ≥2yrs: (≤40kg): 2mg/kg, may increase to 4mg/kg every 4 weeks if inadequate response; (>40kg): 150mg, may increase to 300mg every 4 weeks if inadequate response.
Ilaris Contraindications
Not Applicable
Ilaris Boxed Warnings
Not Applicable
Ilaris Warnings/Precautions
Warnings/Precautions
Do not start in patients with active infection; discontinue if serious infection develops. History of recurring infections or conditions that predispose to infection. Test for and treat TB before starting therapy. Discontinue if severe hypersensitivity reaction occurs. Patients should receive all recommended vaccines (eg, pneumococcal, influenza) prior to initiating therapy. Macrophage activation syndrome (esp. in Still's disease). Pregnancy. Nursing mothers.
Ilaris Pharmacokinetics
See Literature
Ilaris Interactions
Interactions
Concomitant TNF inhibitors, other IL-1 blockers, live vaccines: not recommended. Monitor warfarin, other agents with narrow therapeutic indexes; may need dose adjustments.
Ilaris Adverse Reactions
Adverse Reactions
Nasopharyngitis, diarrhea, influenza, rhinitis, nausea, headache, bronchitis, gastroenteritis, pharyngitis, inj site reactions, weight increased, musculoskeletal pain, vertigo, abdominal pain; increased risk of infections, malignancies.
Ilaris Clinical Trials
See Literature
Ilaris Note
Not Applicable
Ilaris Patient Counseling
See Literature
